Cubist Pharmaceuticals Announces Second Quarter 2009 Earnings Call

Earnings Conference Call & Webcast on Thursday, July 16th, at 5:00 pm ET
LEXINGTON, Mass.--(Business Wire)--
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will issue
its second quarter 2009 financial results at 4:00 p.m. ET on Thursday, July
16th, 2009, one day earlier than previously indicated. In connection with this
announcement, Cubist will host a conference call and live audio webcast (with
slides) at 5:00 p.m. ET that same day to discuss its second quarter financial
results, business activities, and financial outlook.

As always, the quarterly earnings call will be available via phone and webcast.
The phone call dial-in information is listed below. To access the webcast,
please log on to the Cubist website at cubist.com at least 15 minutes prior to
the start of the call to ensure adequate time for any software downloads that
may be required.

A replay of the webcast and teleconference will be available on Cubist`s website
beginning approximately three hours after the call.

CONFERENCE CALL & WEBCAST INFORMATION
Cubist Pharmaceuticals to announce Q209 Financial Results
Thursday, July 16th, 2009

Earnings Conference Call & Webcast at 5:00 pm ET
Cubist will host a conference call and live audio webcast to discuss its second
quarter 2009
financial results, business activities and financial outlook.

Participant Dial-In Numbers:
Live Participant Dial In (Toll Free): 877-407-8289
Live Participant Dial In (International): 201-689-8341

Dial-In # for Replay Access: (Toll Free) 877-660-6853 (International)
201-612-7415
Replay Passcodes (both required for playback):
Acct #: 351 Conference ID: 326755
For more information: http://www.investorcalendar.com/IC/CEPage.asp?ID=146838

CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.com
Replay will be available for 30 days at www.cubist.com

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
research, development, and commercialization of pharmaceutical products that
address unmet medical needs in the acute care environment. In the U.S., Cubist
markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class
of anti-infectives called lipopeptides. In July 2008, Cubist began promoting
MERREM® I.V. (meropenem for injection) in the United States. MERREM is an
established broad spectrum antibiotic developed by AstraZeneca. The Cubist
product pipeline includes ecallantide, a recombinant human protein in Phase 2
clinical trials - CONSERV-1 and CONSERV-2 - for the reductionof blood loss
during cardiothoracic surgery, and two Phase 1 programs that address unmet
medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the
other in multi-drug resistant (MDR) Gram-negative infections. In addition, the
Company, in collaboration with Alnylam Pharmaceuticals, Inc. (Cambridge, MA),
has a pre-IND and a Phase 2 program underway in novel treatments for respiratory
syncytial virus infections using Alnylam`s RNA-interference technology. Cubist
is headquartered in Lexington, MA. Additional information can be found at
Cubist`s web site at www.cubist.com.

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.

AstraZeneca and MERREM are registered trademarks of the AstraZeneca group of
companies.

Cubist Pharmaceuticals, Inc.
Eileen C. McIntyre, 781-860-8533
Senior Director, Corporate Communications
eileen.mcintyre@cubist.com
or
Weber Shandwick
Tara Murphy, 617-520-7045
tmurphy@webershandwick.com

Copyright Business Wire 2009